Esperion Therapeutis.Inc. buy F1Trader
Start price
16.09.19
/
50%
€33.99
Target price
04.11.21
-
Performance (%)
-17.45%
End price
02.02.21
€28.06
Summary
This prediction ended on 02.02.21 with a price of €28.06. The prediction for Esperion Therapeutis.Inc. disappointed with a performance of -17.45%. F1Trader has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 0.000% | 0.000% | 80.098% | 91.494% |
| iShares Core DAX® | 0.881% | 5.632% | 8.477% | 63.917% |
| iShares Nasdaq 100 | 2.390% | 1.571% | 28.412% | 91.986% |
| iShares Nikkei 225® | 4.269% | 2.521% | 50.984% | 83.957% |
| iShares S&P 500 | 1.171% | 2.545% | 23.603% | 71.357% |
Comments by F1Trader for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Buy Esperion Therapeutis.Inc.